Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus diet and exercise. This study found that the addition of ONGLYZA(TM) (saxagliptin) 5 mg to existing metformin therapy achieved [...]
Tag Archive > Type 2 Diabetes
ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control In Treatment-Naive Adults With Type 2 Diabetes
Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated hemoglobin level (HbA1c)] in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on [...]
Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Orlando, Florida, November 15 (ots/PRNewswire) – Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Efient(R) (prasugrel) achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg [...]
New Study Results Show That Patients Have Higher Treatment Satisfaction With Liraglutide Compared to Exenatide
Montreal (ots/PRNewswire) – New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.[1] To view the Multimedia News Release, please click: http://multivu.prnewswire.com/mnr/prne/novo/37559/ Specifically, among the [...]
NOXXON Pharma AG announces excellent preliminary phase I trial results for Spiegelmer® NOX-E36 – good safety and pharmacodynamic profile and additional good subcutaneous bioavailability
(pressebox) Berlin, 12.10.2009, NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its antiinflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic [...]
EANS-News: DEWB investment holding NOXXON Pharma AG announces excellent preliminary phase I trial results for Spiegelmer® NOX-E36
Good safety and pharmacodynamic profile and additional good subcutaneous bioavailability ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information Utl.: Good safety and pharmacodynamic profile and additional good subcutaneous bioavailability = Berlin, Germany, 12 October 2009 (euro adhoc) – NOXXON Pharma AG, the [...]
Study Finds That ONGLYZA(TM) (saxagliptin) When Added to Metformin was Non-Inferior to JANUVIA (sitagliptin) When Added to Metformin in Reducing Hemoglobin (HbA1c) in Adults With Type 2 Diabetes Mellitus
Princeton, New Jersey and London (ots/PRNewswire) – Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA(TM) (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with [...]
Onglyza(R) (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) (LSE: AZN) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union. Onglyza is indicated as a once-daily 5 mg oral tablet dose in adult patients with type 2 diabetes mellitus [...]
Boehringer Ingelheim’s Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptin
Ingelheim, Germany (ots/PRNewswire) – – For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III clinical trials programme consistently support the favourable efficacy and safety [...]
Ilaris(R) Recommended for European Approval as New Biologic Drug to Treat a Rare but Serious Group of Auto-Inflammatory Diseases
Basel, Switzerland (ots/PRNewswire) – – Not For US Media – Set to Become First Medicine in EU to Treat Patients Aged Four and Older Suffering From Life-Long Cryopyrin-Associated Periodic Syndrome (CAPS)(1) – Ilaris Targets Interleukin-1 Beta (IL-1 Beta), a key Driver of Inflammation(1,2,3) – Studies Ongoing in Other Diseases Involving IL-1 Beta Such as Gout, [...]
New Tonalin® CLA Study Offers Compelling Benefits for Post-Menopausal Women with Type 2 Diabetes
(pressebox) La Grange, Ill., 10.07.2009, Cognis’ Tonalin® CLA is a safe and effective way to reduce body fat mass and preserve lean muscle mass in post-menopausal women with type 2 diabetes, according to the first study of its kind published in the American Journal of Clinical Nutrition(1). Although the fat reduction effect of CLA has [...]
LAP-BAND(TM) ist in Europa das erste Adipositas-Interventions-System zur Gewichtsgewichtsreduktion, das bei Typ-2-Diabetes eine Verbesserung oder Rückbildung erzielen konnte
London (ots/PRNewswire) – – Medizinische Experten fordern, dass der Einsatz von Magenbändern bei der Behandlung von adipösen Patienten mit Typ-2-Diabetes stärker berücksichtigt werden sollte Das LAP-BAND(TM) AP System von Allergan zur Behandlung der Adipositas hat als erstes Gewichtsreduktionssystem, das eine Verbesserung oder Rückbildung eines bestehenden Typ-2-Diabetes herbeiführt, eine offizielle europäische Zulassung erhalten. Der Type-2-Diabetes hat [...]
ONGLYZA(TM) (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (LSE: AZN) today announced that their marketing authorisation application for ONGLYZA(TM) (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or [...]
New Data From Boehringer Ingelheim’s Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany (ots/PRNewswire) – – Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year’s American Diabetes Association Annual Meeting (ADA) show clinically relevant and statistically significant reductions in [...]
New NICE Guideline for Type 2 Diabetes Recognises Benefits From Newer Agents for Blood Glucose Control
London (ots/PRNewswire) – – For Healthcare and Pharmaceutical Correspondents Only – NICE Recommends Considering DPP-4 Inhibitors as a Second Line Treatment Option in Appropriate Patients Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical Excellence (NICE) in the [...]
